CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Other Events
Item8.01
| Other Events |
On March15, 2017, the Company issued a press release announcing
the positive top-line results from an
investigator-sponsored trial evaluating Firdapse (amifampridine
phosphate) as a treatment for Myasthenia Gravis patients with
anti-MuSK antibodies.
A copy of the
Companys press release is attached as Exhibit 99.1 to this Form
8-K and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 | Press release issued by the Company on March15, 2017. |
2
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy. CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Recent Trading Information
CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) closed its last trading session 00.00 at 1.17 with 1,900,531 shares trading hands.
